ACE and Huntington disease: Of the 136 HD patients, 82 (60.3%) were taking calcium channel blockers (CCBs), 72 (52.9%) were taking β-blockers, and 29 (21.3%) patients were taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).